Nidec Announces in Relation to Disclosure Information Regarding Consolidated Financial Statements
KYOTO, Japan, May 29, 2025--(BUSINESS WIRE)--Nidec Corporation hereby announces that at the Board of Directors meeting held today, it was resolved to post the contents of the attachment on its Internet website (address: https://www.nidec.com/en/ir/event/meeting/).
The audits of overseas subsidiaries are taking time, and we have not yet received the accounting auditor's report on the consolidated financial statements.
The accounting auditor's report on the consolidated financial statements is currently being prepared in time for the 52nd Annual General Meeting of Shareholders, scheduled to be held on June 20, 2025, but is yet to be determined. We will notify you as soon as we receive it.
(Attachment)
To our shareholders
Disclosure information regarding consolidated financial statements
We would like to express our sincere gratitude to our shareholders for their ongoing support and encouragement.
Our 52nd business report, financial statements, and consolidated financial statements have already been submitted to the Audit and Supervisory Committee and the accounting auditor. However, due to the time required for the audits of our overseas subsidiaries, we have not yet received the accounting auditor's audit report on the consolidated financial statements.
We have already sent the materials for the 52nd Annual General Meeting of Shareholders to shareholders who have requested to receive them in writing. These materials include the accounting auditor's audit report on the consolidated financial statements and the audit report of the Audit and Supervisory Committee, the contents of which are subject to receipt of the accounting auditor's audit report. These audit reports were prepared and sent in anticipation of receiving the accounting auditor's audit report on the consolidated financial statements. However, as stated above, we have not yet received the accounting auditor's audit report on the consolidated financial statements at this time.
In this regard, the audit reports of the Audit and Supervisory Committee, which are based on the assumption that the audit report of the accounting auditor on the consolidated financial statements has not yet been received at this time, are posted on the websites listed in the notice of the meeting. In addition, once the accounting auditor's audit report on the consolidated financial statements has been received and the Audit and Supervisory Committee's audit based on said audit report has been completed, the Audit and Supervisory Committee's audit report and the accounting auditor's audit report on the consolidated financial statements will be posted on the website.
Furthermore, based on the results of the accounting audits conducted by the accounting auditors for the consolidated financial statements, if any corrections are made to the information to be disclosed in the consolidated financial statements going forward, we will take measures such as promptly posting such corrections on our website (address: https://www.nidec.com/en/ir/event/meeting/). We would appreciate your understanding and cooperation in this matter.
May 29, 2025Mitsuya KishidaRepresentative Director and PresidentNIDEC Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529934476/en/
Contacts
Teruaki UragoGeneral ManagerInvestor Relations+81-75-935-6140ir@nidec.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
26 minutes ago
- Bloomberg
Emerging-Market Stocks Gain as China Data Refuel Stimulus Hopes
Emerging-market stocks advanced for the first time in three days as a slump in China's factory activity increased bets on more economic stimulus. The benchmark MSCI EM index rose 0.4% after data showing China's manufacturing sector had its worst slump since September 2022, with higher tariffs taking a toll on smaller exporters. The onshore CSI 300 Index gained 0.3%, while a gauge of Chinese stocks listed in Hong Kong jumped 1.9%.
Medscape
27 minutes ago
- Medscape
Tocilizumab, Alone or With Methotrexate, Potent in Active RA
Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODOLOGY: Researchers conducted a phase 3 trial at 19 sites in China between July 2017 and August 2022 to evaluate the efficacy of subcutaneous tocilizumab, administered either as monotherapy or in combination with methotrexate, in 340 patients with moderate to severe active RA (mean age, 47.5 years; 86.5% women). The patients had a diagnosis of RA for ≥ 6 months, had received methotrexate for ≥ 12 weeks, experienced treatment failure with at least one csDMARD (including methotrexate), had at least six swollen joints and at least eight tender joints, and had either a high-sensitivity C-reactive protein level ≥ 4 mg/L or an erythrocyte sedimentation rate ≥ 28 mm/h. Patients were randomly assigned to receive tocilizumab-methotrexate combination therapy (n = 136), tocilizumab monotherapy with placebo (n = 136), or methotrexate monotherapy with placebo (n = 68) for 24 weeks. Tocilizumab (162 mg) was administered subcutaneously once every 2 weeks, and methotrexate (10-25 mg) was administered orally once every week. Patients achieving a Disease Activity Score in 28 joints of ≤ 3.2 after 24 weeks continued their randomly assigned treatment, whereas those with a score > 3.2 switched to unblinded tocilizumab-methotrexate treatment. The primary efficacy endpoint was the proportion of patients who achieved a ≥ 20% improvement in the American College of Rheumatology (ACR20) response criteria at 24 weeks, with long-term efficacy analyzed at 48 weeks and safety monitored for 56 weeks. TAKEAWAY: The ACR20 response rate at 24 weeks was higher in the tocilizumab-methotrexate combination therapy (52.9%) and tocilizumab monotherapy (50.0%) groups than in the methotrexate monotherapy group (25.0%), with significant differences of 27.9 and 25.0 percentage points, respectively ( P < .001 for both). < .001 for both). Long-term efficacy analysis at 48 weeks showed maintained or improved efficacy in patients continuing tocilizumab monotherapy or tocilizumab-methotrexate combination therapy, with an improved disease status in those who switched to unblinded tocilizumab-methotrexate treatment at 24 weeks. Tocilizumab was well tolerated as both monotherapy and in combination with methotrexate, with no new safety signals. IN PRACTICE: 'Subcutaneous tocilizumab, both as monotherapy and in combination with methotrexate, had clinically significant efficacy compared with methotrexate monotherapy in Chinese patients with moderate to severe active RA,' the authors wrote. SOURCE: This study was led by Tian Liu, MD, Peking University People's Hospital in Beijing, China. It was published online on May 19, 2025, in JAMA Network Open . LIMITATIONS: Only Chinese patients were included, thus limiting the generalizability of the findings. Researchers did not include imaging analysis. The recruitment was extended over a period of 4 years owing to the COVID-19 pandemic, which resulted in missing the efficacy assessments and tocilizumab administration in some patients. DISCLOSURES: This study received funding from and was conducted in collaboration with F. Hoffmann-La Roche Ltd. Three authors reported receiving grants from various pharmaceutical companies, including Roche. Two authors reported being employed by Roche (China) Holding.
Bloomberg
27 minutes ago
- Bloomberg
Japanese PM Ishiba Maneuvers To Outflank Rivals, Reports Suggest
Japanese Prime Minister Shigeru Ishiba appears to be trying to keep his party rivals in check as he wrestles with the US over tariffs and prepares for an upper house election in less than two months. Ishiba is considering dissolving the lower house of parliament if the opposition submits a no-confidence vote during the current session through late June, Japanese media outlets such as the Asahi newspaper reported on Tuesday, citing unnamed government sources.
